© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.
James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the rationale for developing therapies for renal cell carcinoma that target HIF2α.